Manhattan Pharmaceuticals to Present at Oppenheimer Diabetes Conference
Aug 31, 2005
NEW YORK, NY AUG 31 - Manhattan Pharmaceuticals, Inc. (MHTT.OB) said Douglas Abel, president and chief executive officer, will present an overview of the company and its obesity drug Oleoyl-estrone at the Oppenheimer & Co. Diabetes Conference at The Warwick Hotel, New York, Wednesday September 7.
Mr. Abel's presentation will take place at 11:35 am and will be webcast live at:
http://www.internetvideochannel.com/oppenheimer/diabetes.htm. An archived version of the webcast will be available for 30 days.
About Manhattan Pharmaceuticals, Inc.
Manhattan Pharmaceuticals, Inc. (www.manhattanpharma.com), a development stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for weight loss. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures.
Nicholas J. Rossettos, CPA
Chief Financial Officer
Manhattan Pharmaceuticals, Inc.